We conducted a comparative study of the in situ immune patterns of PTs and mLNs of NSCLC patients regarding the spatial distributions and densities of CD3+ and CD8+ TILs and the PD-L1 expression statuses of tumor cells and stromal CD3+ TILs. This evidence concerns the gene CD8A and neoplasm.